HomeCompareKAEPY vs JNJ

KAEPY vs JNJ: Dividend Comparison 2026

KAEPY yields 2.34% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $6.7K in total portfolio value· pulled ahead in Year 8
10 years
KAEPY
KAEPY
● Live price
2.34%
Share price
$8.54
Annual div
$0.20
5Y div CAGR
2.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.6K
Annual income
$340.30
Full KAEPY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — KAEPY vs JNJ

📍 JNJ pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKAEPYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KAEPY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KAEPY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KAEPY
Annual income on $10K today (after 15% tax)
$198.97/yr
After 10yr DRIP, annual income (after tax)
$289.26/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,696.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KAEPY + JNJ for your $10,000?

KAEPY: 50%JNJ: 50%
100% JNJ50/50100% KAEPY
Portfolio after 10yr
$26.9K
Annual income
$2,514.85/yr
Blended yield
9.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

KAEPY
No analyst data
Altman Z
1.2
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KAEPY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKAEPYJNJ
Forward yield2.34%2.13%
Annual dividend / share$0.20$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR2.1%28%
Portfolio after 10y$23.6K$30.3K
Annual income after 10y$340.30$4,689.40
Total dividends collected$2.9K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KAEPY vs JNJ ($10,000, DRIP)

YearKAEPY PortfolioKAEPY Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,939$239.00$10,592$272.30+$347.00KAEPY
2$11,954$249.47$11,289$357.73+$665.00KAEPY
3$13,051$260.14$12,123$472.89+$928.00KAEPY
4$14,236$271.01$13,141$629.86+$1.1KKAEPY
5$15,514$282.07$14,408$846.81+$1.1KKAEPY
6$16,894$293.32$16,021$1,151.60+$873.00KAEPY
7$18,381$304.77$18,122$1,588.22+$259.00KAEPY
8← crossover$19,984$316.42$20,930$2,228.20$946.00JNJ
9$21,711$328.26$24,792$3,191.91$3.1KJNJ
10$23,571$340.30$30,274$4,689.40$6.7KJNJ

KAEPY vs JNJ: Complete Analysis 2026

KAEPYStock

The Kansai Electric Power Company, Incorporated engages in electricity, gas and heat supply, and telecommunication businesses in Japan. It operates through four segments: Energy Business, Power Transmission and Distribution Business, Information and Communication Business, and Life and Business Solution Business. The company generates power from thermal, hydropower, wind, biomass, and nuclear power generation plants. It is also involved in the power transmission and distribution business; provision of information and communication services for homes and businesses under the eo Hikari brand; mobile business under the mineo business; corporate solution business; and real estate leasing, sale, and management activities; and leisure, leasing, call center management, dispatching, medical health care, and home security businesses. In addition, the company engages in the maintenance and construction of power distribution and electricity lines, thermal and nuclear power generation facilities, and information and communication equipment; utility pole advertising; manufacture, supply, and sale of gas; manufacture and sale of power distribution equipment, such as overhead wire hardware, insulators/bushings, steel pipe columns, concrete columns, etc.; housing equipment sales; remodeling work; and passenger/freight transportation. Further, it is involved in the survey and research on safety technology for nuclear power generation, survey/design /construction supervision related to civil engineering/architecture, etc.; acceptance/ storage/vaporization /delivery of LNG; condominium high-voltage batch power reception service business; fuel trading and transportation; corporate settlement; and provision of survey, analysis, consulting, and construction services related to the environment, civil engineering, and architecture, as well as public relations and engineering services The Kansai Electric Power Company, Incorporated was founded in 1951 and is headquartered in Osaka, Japan.

Full KAEPY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this KAEPY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KAEPY vs SCHDKAEPY vs JEPIKAEPY vs OKAEPY vs KOKAEPY vs MAINKAEPY vs ABBVKAEPY vs MRKKAEPY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.